4.3 Review

Antigen-specific immunotherapies in type 1 diabetes

Journal

Publisher

ELSEVIER GMBH
DOI: 10.1016/j.jtemb.2022.127040

Keywords

Type 1 diabetes mellitus; Antigen-specific immunotherapies; Immune tolerance; ZnT8; Prevention

Funding

  1. National Natural Science Foundation of China [82070796]

Ask authors/readers for more resources

Type 1 diabetes mellitus is an autoimmune disease caused by the destruction of pancreatic beta cells. Immune regulation with pancreatic islet auto-antigens is a specific and safe treatment for T1DM. Early screening of autoantibodies can help identify high-risk individuals and prevent T1DM. Inducing self-tolerance in pre-diabetic patients can also slow down autoimmunity and achieve secondary prevention.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease caused by the destruction of pancreatic beta cells, in which immune system disorder plays an important role. Finding a cure for T1DM and restoring beta cell function has been a long-standing goal. Research has shown that immune regulation with pancreatic islet auto-antigens may be the most specific and safe treatment for T1DM. Immunological intervention using diabetogenic autoantigens as a target can help identify T1DM in high-risk individuals by early screening of autoantibodies (AAbs) before the loss of pancreatic islet function and thus achieve primary prevention of T1DM. However, induction of self-tolerance in patients with pre-diabetes can also slow down the attack of autoimmunity, and achieve secondary prevention. Antigen-based immune therapy opens up new avenues for the prevention and treatment of T1DM. The zinc transporter 8 (ZnT8) protein, presents in the serum of pre-diabetic and diabetic patients, is immunogenic and can cause T1D autoimmune responses. ZnT8 has become a potential target of humoral autoimmunity; it is of great significance for the early diagnosis of T1D. ZnT8-specific CD8+ T cells can be detected in most T1DM patients, and play a key role in the progression of T1D. As an immunotherapy target, it can improve the dysfunction of beta cells in T1DM and provide new ideas for the treatment of T1D. In this review, we summarize research surrounding antigen-specific immunotherapies (ASI) over the past 10 years and the ZnT8 antigen as an autoimmune target to induce self-tolerance for T1DM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available